Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience's commitment to precision neuropsychiatry is underscored by its robust pipeline, featuring several clinical-stage assets, including ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300, which are aimed at treating psychiatric disorders through biomarker-guided approaches. The company boasts a strong cash position of approximately $275 million, enabling it to effectively advance its clinical programs and sustain operations. Promising clinical outcomes, such as significantly improved MADRS scores in ALTO-207 trials and positive EEG measure trends, further reinforce the potential for successful therapeutic interventions and a solid growth trajectory in the field of personalized psychiatry.

Bears say

Alto Neuroscience faces significant challenges affecting its financial outlook, primarily due to the disappointing results from its Phase 2 proof-of-concept trial for ALTO-101, which failed to achieve statistical significance on key endpoints. The inherent high failure rates associated with clinical trials for depression, attributed to patient heterogeneity and elevated placebo responses, further complicate the company's ability to successfully bring its products to market. Additionally, there is a looming risk concerning the protection of the company's intellectual property; any potential issues regarding patents could compromise asset value and lead to negative revisions of the company's overall valuation.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.